QLF31907
- Generic Name
- QLF31907
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Neoplasm
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06394713
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT05823246
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳West China Hospital, Chengdu, Sichuan, China
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05150405
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath